Aurion Biotech Appoints Edward J. Holland, M.D., as Chief Medical Officer and Eris P. Jordan, O.D., as Chief Development Officer
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, a clinical-stage regenerative medicine company whose mission is to restore vision to millions of patients, today announced the appointments of Edward J. Holland, M.D., as Chief Medical Officer, and Eris P. Jordan, O.D., as Chief Development Officer.
Aurion Biotech is developing AURN001, an investigational, single-administration, allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial disease, a condition that causes progressive vision loss in millions of people worldwide.
Dr. Holland has been a key supporter of Aurion since its inception, serving as Chair of the Medical Advisory Board and leading the first team of U.S. corneal surgeons to deliver the cell therapy developed by Aurion Biotech, based on foundational technology from Professor Shigeru Kinoshita at Kyoto Prefecture University of Medicine. His insights and clinical leadership have helped shape the trajectory of Aurion's development program.
Dr. Jordan, a co-founder of Aurion, has been instrumental at every stage of the company's clinical journey. She led the foundational clinical trials in El Salvador, including the IOTA and ESCALON studies, and has since overseen the expansion of Aurion's clinical development program into North America. Her contributions have brought Aurion's mission to life — grounded in tireless advocacy for patients and deep collaboration with the global corneal surgeon community.
'I've had the privilege of knowing Dr. Holland for over a decade,' said Arnaud Lacoste, Ph.D., M.B.A., Chief Executive Officer of Aurion. 'His dedication to patients and his leadership in corneal care have been instrumental to the success of our program. His appointment as Chief Medical Officer further strengthens our clinical and scientific foundation as we move toward late-stage development and, ultimately, broader patient access.'
'Over the past four years, Dr. Jordan has poured her heart into this program,' Lacoste continued. 'Her leadership of our global clinical trials has been extraordinary, and her commitment to patients and surgeons alike reflects who we are as a company. I'm honored to continue working with Eris as Chief Development Officer.'
Dr. Holland added, 'Joining Aurion in this capacity is both exciting and deeply meaningful. I've seen firsthand the transformative potential of AURN001, and I look forward to helping the team bring this therapy to patients who urgently need new options.'
Dr. Jordan commented, 'This program has always been about patients — those we've met and those still waiting. I'm grateful to lead the development of AURN001, and to work alongside a team so deeply committed to scientific excellence and to the people we serve.'
About Edward J. Holland, M.D.
Dr. Holland is a globally recognized leader in cornea and external disease. His numerous honors include the Senior Achievement and Life Achievement Honor Awards from the American Academy of Ophthalmology, the Binkhorst and Lindstrom Medals from the American Society of Cataract and Refractive Surgery, and the Castroviejo Award from the Cornea Society. He has been named among the 'Best Doctors in America' and has published extensively in both basic and clinical research, with over 300 peer-reviewed articles. Dr. Holland was the co-principal investigator of the Cornea Donor Study, the largest clinical trial ever conducted in the field of cornea, and he has co-edited five editions of Cornea, the most widely read textbook on corneal disease and surgery.
About Eris P. Jordan, O.D.
Dr. Jordan brings over two decades of experience across clinical practice and the ophthalmic industry, and she continues to serve as a practicing clinician specializing in cornea and anterior segment. Prior to co-founding Aurion Biotech and serving as Vice President of Clinical and Medical Affairs, she held leadership roles including Senior Director of Medical Affairs at CorneaGen, Clinical Team Lead and Surgeon Educator at AcuFocus, Inc., and Executive Clinical Outcomes Specialist in Bausch & Lomb's surgical division. Before transitioning to industry, Dr. Jordan spent a decade in direct patient care and served as Clinic Director for a cornea and anterior segment surgical practice. She completed her post-graduate training at the Bascom Palmer Eye Institute—the top-ranked U.S. eye care institute—and earned both her Doctor of Optometry and Bachelor of Optical Sciences degrees in a fast-tracked program from Salus University, graduating with highest clinical honors.
About Aurion Biotech
Aurion Biotech's mission is to restore vision to millions of patients with life-changing regenerative therapies. The company is developing AURN001, an investigational cell therapy for corneal endothelial disease. AURN001 is the first cell therapy for the corneal endothelium to be commercially launched (in Japan) and is advancing through clinical development in North America. Aurion received the prestigious Prix Galien award for Best Start-Up in Biotech in 2022. In 2025, Alcon acquired majority ownership of Aurion Biotech. For more information, visit www.aurionbiotech.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
CEA Opens Shanghai–Auckland–Buenos Aires "New International Land-Sea Trade Corridor" to First Bridge China and South America
SHANGHAI--(BUSINESS WIRE)--On June 18, 2025, China Eastern Airlines (CEA) and Auckland Airport signed a cooperation agreement in Shanghai. According to the plan, CEA will launch commercial flights in December 2025 from Shanghai Pudong International Airport to Ministro Pistarini International Airport via Auckland Airport. The signing ceremony was attended by government officials, corporate representatives, and heads from relevant departments. New Zealand's Prime Minister Christopher Luxon highlighted that the new route will enhance global connectivity by linking Auckland with the dynamic economies of Asia and South America. He also announced that New Zealand will implement a visa-free transit policy for Chinese travelers passing through Auckland. Since the opening of the route to Auckland in 2014, CEA has shown strong growth. Chairman Wang Zhiqing stated that the airline will leverage its Shanghai hub to accelerate the construction of its global route network. The new route will serve as a vital bridge among New Zealand, China, the Asia-Pacific region, and South America, supporting the Belt and Road Initiative. Auckland Airport expressed satisfaction with the imminent realization of the jointly envisioned " New International Land-Sea Trade Corridor". CEA, Auckland Airport's key partner and now the leading carrier on the China–New Zealand route, has maintained steady operations and consistently expanded capacity. The new service, to be operated twice weekly by Boeing 777, will be the only direct air link between Argentina and China, filling the gap in direct air services between the two nations. The "New International Land-Sea Trade Corridor" shortens travel time by 4–5 hours versus European or North American routes and offers direct flights, while also reducing jet lag—passengers only face a 4-hour time difference when transiting through Auckland, as opposed to 12 hours via traditional Western routes. CEA plans to apply for fifth freedom for this route, enabling passenger and cargo transport in Auckland, boosting economic, trade, and people-to-people exchanges among New Zealand, China, and Argentina. Currently, CEA operates flights from Auckland to both Shanghai Pudong and Hangzhou Xiaoshan. Following the new route launch, CEA will boost New Zealand–China capacity deployment, increasing Auckland–Shanghai flights from 7 to 9 weekly. Note: The new route remains subject to final regulatory approval.
Associated Press
2 hours ago
- Associated Press
ICEYE to deliver space-based ISR capability to the Royal Netherlands Air Force
Royal Netherlands Air Force partners with ICEYE to establish sovereign, space-based ISR capability. HELSINKI, June 23, 2025 /PRNewswire/ -- ICEYE, the European space and defense technology company, and global leader in Synthetic Aperture Radar (SAR) satellite operations for high-resolution Earth observation and persistent monitoring, has been selected to provide Intelligence, Surveillance, and Reconnaissance (ISR) systems to the Royal Netherlands Air Force (RNLAF). This agreement marks a significant advancement in the Netherlands' space-based defense capabilities and its commitment to strengthening national security through sovereign ISR assets. Under the agreement with the Royal Netherlands Air Force, ICEYE will deliver a full suite of ISR solutions to the RNLAF, including four 25cm resolution SAR satellites, a local ground segment and antenna, and a mobile ground segment featuring an autonomous, AI-driven imagery intelligence hub. The contract also includes the sale of satellite data from ICEYE's existing constellation. This collaboration lays the groundwork for the first operational Dutch military satellite mission and was realized in a record timeframe - just four months from contract signing to the delivery of the first system component. The rapid delivery underscores ICEYE's unique ability to offer sovereign ISR capabilities on an accelerated timeline, aligning with the Netherlands' defense and space strategies. By selecting ICEYE, the RNLAF and the Netherlands Ministry of Defence have been able to significantly accelerate the implementation of their national defense and space strategies, which call for sovereign and independent ISR capabilities. Additionally, ICEYE will deepen its collaboration with the Netherlands and its local industry, strengthening and leveraging the local high-tech space and defense industry, as well as related capabilities in the region. 'This agreement is a step in European rearmament efforts for securing the defense of European nations. ICEYE is proud to provide the Netherlands with a sovereign and independent satellite ISR capability with the country's first operational military satellite mission. By delivering this system at an unprecedented speed, ICEYE is ensuring that the Netherlands has access to objective, reliable, and actionable intelligence. As a European provider, ICEYE is ideally positioned to provide European nations with a common and capable asset for space-based ISR activities,' said Rafal Modrzewski, CEO and Co-founder of ICEYE. 'We are pleased to partner with ICEYE to develop the Royal Netherlands Air Force's space-based defense capabilities. This collaboration positions the Netherlands at the forefront of European countries investing in this cutting-edge technology. Additionally, this recognizes the critical role of the space domain in national defense and underscores the Netherlands' commitment to securing its interests in this vital new frontier of defense,' said Lieutenant General André Steur, Commander of the Royal Netherlands Air Force. ICEYE's European, sovereign, non-ITAR technology enables the rapid delivery of ISR capabilities to its customers. The ICEYE system is also engineered to enable sharing capacity and cross-tasking with other nations, if desired, to optimize the use of the combined fleets and enhance the collective space defense capabilities of European and allied nations. About ICEYE ICEYE delivers unparalleled persistent monitoring capabilities to detect and respond to changes in any location on Earth, faster and more accurately than ever before. Owning the world's largest synthetic aperture radar (SAR) satellite constellation, ICEYE provides objective, near real-time insights, ensuring that customers have unmatched access to actionable data, day or night, even in challenging environmental conditions. As a trusted partner to governments and commercial industries, ICEYE delivers intelligence in sectors such as defense and intelligence, insurance, natural catastrophe response and recovery, security, maritime monitoring, and finance, enabling decision-making that contributes to community resilience and sustainable development. ICEYE operates internationally with offices in Finland, Poland, Spain, the UK, Australia, Japan, UAE, Greece, and the US. We have more than 700 employees, inspired by the shared vision of improving life on Earth by becoming the global source of truth in Earth Observation. Media contact: [email protected] Visit and follow ICEYE on LinkedIn and X for the latest updates and insights. View original content to download multimedia: SOURCE ICEYE
Business Wire
6 hours ago
- Business Wire
2025 Travelers Championship Generates More Than $4 Million for Charity
HARTFORD, Conn.--(BUSINESS WIRE)--The Travelers Companies, Inc. (NYSE: TRV) today announced that the 2025 Travelers Championship – a PGA TOUR Signature Event – generated more than $4 million for over 215 nonprofits, both record highs. Travelers also set a record this year as the longest-running title sponsor in the tournament's history. In the 19 years the company has been title sponsor, the Travelers Championship has generated tens of millions of dollars for charity. Alan Schnitzer, Chairman and Chief Executive Officer of Travelers, said, 'This week truly captured what makes the Travelers Championship so special – world-class golf played before an enthusiastic crowd, all united by a shared purpose. It is a formula that led to a great week of golf and more money raised for charity than ever before. For 19 years, we have been honored to bring the PGA TOUR to Connecticut, and every year I am inspired by the passion of the players, the dedication of our fans and the incredible support from volunteers and partners who rally around our mission to give back. In addition to supporting vital charitable causes, we are proud that the tournament also generates significant economic activity for the state of Connecticut. Congratulations to our 2025 champion, Keegan Bradley, for rising to the top of one of the strongest fields in the game. We are already looking forward to making next year's tournament even more memorable.' The Travelers Championship donates 100% of its net proceeds to nonprofits. This year's primary beneficiary is The Hole in the Wall Gang Camp, an organization based in Ashford, Connecticut, that provides a traditional summer camp experience for children with serious illnesses. Many other worthy charities – spanning arts and culture, education, health care, housing, human services, mental health, food insecurity, science and technology, and youth development – also benefit from their involvement with the Travelers Championship. Andy Bessette, Executive Vice President and Chief Administrative Officer of Travelers, said, 'The Travelers Championship extends far beyond tournament week. We have created a community of fans that spans the region, and it is because of their support that we are able to make such an impact on so many charities, the true winners of the Travelers Championship. We are so grateful to the world's best PGA TOUR players for delivering another tremendous competition that we will all remember for some time.' The 2026 Travelers Championship is scheduled to take place June 22-28 at TPC River Highlands in Cromwell, Connecticut. For more information, visit About Travelers
